[1]
A. Tekeli Taşkömür, Özlem Erten, and B. Dilbaz, “Comparison of two drospirenone-containing oral contraceptives for their effect on the ovary, menstrual cycle, acne, and side-effect profile: 20 µg ethinylestradiol/3 mg drospirenone (24/4) versus 30 µg ethinylestradiol/3 mg drospirenone (21/7)”, J Surg Med, vol. 5, no. 11, pp. 1099–1103, Nov. 2021.